NICE’s track record in cancer drugs: the impact of the CDF and interim fundingLeela Barham looks back to before the Cancer Drugs Fund and how recommendations have changed through CDF 1.0 Share XNICE’s track record in cancer drugs: the impact of the CDF and interim fundinghttps://pharmaphorum.com/views-and-analysis/nices-track-record-in-cancer-drugs-the-impact-of-the-cdf-and-interim-funding/
MSD’s Keytruda plus chemo backed by NICE for lung cancerMerck & Co/MSD’s Keytruda can be provided via the Cancer Drugs Fund for first-line treatment of non-small cell Share XMSD’s Keytruda plus chemo backed by NICE for lung cancerhttps://pharmaphorum.com/news/msds-keytruda-plus-chemo-backed-by-nice-for-lung-cancer/
NICE backs Bayer’s Xarelto in new stroke and heart attack prevention useBayer’s Xarelto (rivaroxaban) can be funded by the NHS to prevent strokes and heart attacks in high-risk adults Share XNICE backs Bayer’s Xarelto in new stroke and heart attack prevention usehttps://pharmaphorum.com/news/nice-backs-bayers-xarelto-in-new-stroke-and-heart-attack-prevention-use/
NICE expands funding for AstraZeneca’s high potassium drugNICE has recommended extended funding on the NHS for AstraZeneca’s high potassium drug Lokelma in final draft guidance. Share XNICE expands funding for AstraZeneca’s high potassium drughttps://pharmaphorum.com/news/nice-expands-funding-for-astrazenecas-high-potassium-drug/
NICE backs funding for AZ’s Lynparza ovarian cancer maintenance therapyNICE has recommended interim funding on England’s NHS for AstraZeneca’s ovarian cancer drug Lynparza in the earlier stages Share XNICE backs funding for AZ’s Lynparza ovarian cancer maintenance therapyhttps://pharmaphorum.com/news/nice-backs-funding-for-azs-lynparza-ovarian-cancer-maintenance-therapy/
NICE reviews number crunching methods as advanced technologies hit marketNICE is to review how it develops guidance on drugs, focusing on issues such as modifiers used in Share XNICE reviews number crunching methods as advanced technologies hit markethttps://pharmaphorum.com/news/nice-reviews-number-crunching-methods-as-advanced-technologies-hit-market/
Who will pay the price for inaction on superbugs?While the UK government has been applauded for its efforts in raising awareness about antimicrobial resistance, its efforts Share XWho will pay the price for inaction on superbugs?https://pharmaphorum.com/r-d/views-analysis-r-d/who-will-pay-the-price-for-inaction-on-superbugs/
NICE numbers at 20Leela Barham takes a look at NICE’s stats on Technology Appraisals to see how the agency has changed Share XNICE numbers at 20https://pharmaphorum.com/views-analysis-market-access/nice-numbers-20/
NICE changes its mind on Novartis’ Kisqali for breast cancerNICE has backed NHS use of Novartis’ CDK4/6 inhibitor Kisqali alongside fulvestrant for breast cancer patients in England Share XNICE changes its mind on Novartis’ Kisqali for breast cancerhttps://pharmaphorum.com/news/nice-changes-its-mind-on-novartis-kisqali-for-breast-cancer/
